Another US Stelara Settlement Arrives, This Time For Fresenius And Formycon
Deal With Johnson & Johnson Allows US Biosimilar Ustekinumab Entry In 2025
• By David Wallace
The pieces are starting to fall into place for a series of ustekinumab biosimilar launches in the US in 2025 • Source: Shutterstock 
